Brief: Mereo Biopharma Announces Positive Desmosine Biomarker Data From An Interim Analysis Of An Investigator Initiated Study Of Alvelestat In Bronchiolitis Obliterans Syndrome (Bos)

Mereo BioPharma

02/06/2021 13:17

June 2 (Reuters) - Mereo Biopharma Group PLC  MAH0y.F :
    * MEREO BIOPHARMA ANNOUNCES POSITIVE DESMOSINE BIOMARKER
DATA FROM
AN INTERIM ANALYSIS OF AN INVESTIGATOR INITIATED STUDY OF
ALVELESTAT IN BRONCHIOLITIS OBLITERANS SYNDROME (BOS)
    * MEREO BIOPHARMA GROUP PLC - PHASE 1B/2 STUDY PLANS TO
RECRUIT A
TOTAL OF 30 PATIENTS
    * MEREO BIOPHARMA GROUP PLC - IN PHASE 1 STUDY,
MAXIMUM-TOLERATED
DOSE (MTD) WAS NOT REACHED AND ALVELESTAT WAS WELL TOLERATED
    * MEREO - ALL SIX PATIENTS WITH ELEVATED DESMOSINE LEVELS AT
BASELINE SHOWED REDUCTION IN DESMOSINE WITHIN SUBJECT DOSE
ESCALATION PERIOD BY WEEK 8
    * MEREO BIOPHARMA - ADDITIONAL BIOMARKER ANALYSES OF FIRST
SEVEN
PATIENTS ARE BEING CONDUCTED BY DR. PAVLETIC, TEAM, SUPPORTED BY
MEREO
    * MEREO BIOPHARMA GROUP PLC - ADDITIONAL BIOMARKER ANALYSES
OF
FIRST SEVEN PATIENTS ARE EXPECTED TO BE PRESENTED AT ASH 2021

Source text for Eikon:  ID:nGNX4KSx4W 
Further company coverage:  MAH0y.F 

 ((Reuters.Briefs@thomsonreuters.com;))